DTx Pharma Expands Research & Operations at New Facility in San Diego, California
"We are very excited to be one of the first biotech companies to move into this state-of-the art lab and office space, joining many other important companies in this emerging area," said Arthur T. Suckow, Co-Founder and CEO of DTx Pharma.
"This new facility represents an important strategic step for DTx. It provides us with a solid foundation to grow our culture, expand our team and speed development and deployment of our fatty acid conjugate technology platform to solve the drug delivery challenges associated with RNA-based medicines," he added.
DTx's new facility in Sorrento Valley, which was completed less than a year ago, will allow the company to internalize its chemistry efforts, broaden the application of its fatty acid conjugate technology, and expand its team and infrastructure to support the future growth of the company.
According to company officials, DTx was launched in August 2017 and completed its $10.6M Series A in January 2020 with investment from FBV Fund I, Eli Lilly, Viva Biotech, ExSight Ventures and the Tech Coast Angels, among others. The company's proprietary delivery technology platform utilizes fatty acids as targeting ligands to enable the delivery of oligonucleotide therapies to tissues and cell types throughout the body.
2022 Top States for Doing Business Provide an Environment for Business Growth
Location Factors in the EV Industry — “Mission Critical” or “Nice to Have”?
2022 Auto/Aero Site Guide
How Are Economic Developers Partnering to Solve Workforce Challenges?
Three Big Challenges Facing the Food & Beverage Industry
Fixing the Supply Chain with AI and Robotics
36th Annual Corporate Survey: Executives Focus on Labor, Energy, Shipping Costs
18th Annual Consultants Survey: Access to Major Markets and Skilled Labor Are Clients’ Primary Concerns